Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- APOG +6.5%, X +1.9% (guidance)
Other news:
- MOB +18.9% (announced an initial purchase order for two of its products from a new customer one of the largest defense contractors in Europe)
- INDI +7% (acquiring EXALOS AG; also files stock offering)
- OBIO +6.4% (FDA granted approval of an investigational device exemption to initiate the global pivotal BACKBEAT study)
- ARQT +5.8% (Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05%)
- STLA +2.3% (resumes UAW negotiations according to Bloomberg)
- VIV +2.3% (provides ANATEL court updates)
- SNV +1.6% (expects an increase in third quarter charge-offs arising from a 10.75%)
- CLF +1.2% (trading in sympathy with X)
- BHG +1.1% (continues to make significant progress towards ACA Insurance Business wind-down)
- INTC +1.1% (ahead of Intel Innovation event)
- BGNE +1% (entered into an agreement with Novartis (NVS) to regain worldwide rights to develop manufacture and commercialize TEVIMBRA; positive regulatory updates in Europe and the U.S. after recently regaining global rights for TEVIMBRA)
Analyst comments:
- CCL +2.1% (upgraded to Hold from Sell at Truist)
- REXR +1.6% (upgraded to Outperform from Peer Perform at Wolfe Research)
- GMED +1.5% (upgraded to Buy from Hold at Stifel)
- CVS +0.9% (upgraded to Outperform from In-line at Evercore ISI)